All Stories

  1. Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer
  2. Fluidity as a key determinant of stability in PEGylated lipid nanoparticles loaded with a TLR7 agonist
  3. Evaluation of nanoencapsulated bevacizumab combined with paclitaxel in a colorectal cancer xenograft model
  4. Structural and functional analysis of polyethylene glycol-coated zein nanoparticles
  5. Enhancing bevacizumab efficacy in a colorectal tumor mice model using dextran-coated albumin nanoparticles
  6. Enhancing Bevacizumab efficacy in a colorectal tumor mice model using Dextran-Coated Albumin Nanoparticles
  7. Mucus-penetrating and permeation enhancer albumin-based nanoparticles for oral delivery of macromolecules: Application to bevacizumab
  8. Mucus-penetrating and permeation enhancer albumin-based nanoparticles for oral delivery of macromolecules: application to bevacizumab
  9. Optimization of Enterotoxigenic Escherichia coli (ETEC) Outer Membrane Vesicles Production and Isolation Method for Vaccination Purposes
  10. Encapsulation of Lactobacillus plantarum in casein-chitosan microparticles facilitates the arrival to the colon and develops an immunomodulatory effect
  11. Oral administration of zein-based nanoparticles reduces glycemia and improves glucose tolerance in rats
  12. Evaluación de toxicidad de nanogeles termosensibles en modelo in vivo
  13. Effect of topical berberine in murine cutaneous leishmaniasis lesions
  14. Immune Response after Skin Delivery of a Recombinant Heat-Labile Enterotoxin B Subunit of Enterotoxigenic Escherichia coli in Mice
  15. Oral Immunogenicity of Enterotoxigenic Escherichia coli Outer Membrane Vesicles Encapsulated into Zein Nanoparticles Coated with a Gantrez® AN–Mannosamine Polymer Conjugate
  16. Zein-Based Nanoparticles as Oral Carriers for Insulin Delivery
  17. Development of a Bacterial Nanoparticle Vaccine Against Escherichia coli
  18. Nanoparticles from Gantrez-based conjugates for the oral delivery of camptothecin
  19. Oral Efficacy of a Diselenide Compound Loaded in Nanostructured Lipid Carriers in a Murine Model of Visceral Leishmaniasis
  20. Development of nanostructured systems using natural polymers to optimize the treatment of inflammatory bowel diseases: A prospective study
  21. In vivo testing of mucus-permeating nanoparticles for oral insulin delivery using Caenorhabditis elegans as a model under hyperglycemic conditions
  22. Protection Conferred by Drinking Water Administration of a Nanoparticle-Based Vaccine against Salmonella Enteritidis in Hens
  23. Zein-based nanocarriers for the oral delivery of insulin. In vivo evaluation in Caenorhabditis elegans
  24. Dinámica de la densidad de probabilidad en la región interna de un potencial doble delta de Dirac
  25. Berberine-Loaded Liposomes for the Treatment of Leishmania infantum-Infected BALB/c Mice
  26. Protective Passive Immunity in Escherichia coli ETEC-Challenged Neonatal Mice Conferred by Orally Immunized Dams with Nanoparticles Containing Homologous Outer Membrane Vesicles
  27. Zein-based nanoparticles for the oral delivery of insulin
  28. Zein nanoparticles improve the oral bioavailability of resveratrol in humans
  29. Protein-based nanoparticles for drug delivery purposes
  30. Intranasal delivery system of bacterial antigen using thermosensitive hydrogels based on a Pluronic-Gantrez conjugate
  31. Preparación, radiomarcaje con 99mTc y 67Ga y estudios de biodistribución de nanopartículas de albúmina con recubrimientos poliméricos
  32. In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer
  33. Encapsulation of probiotics in soybean protein-based microparticles preserves viable cell concentration in foods all along the production and storage processes
  34. Oral Immunogenicity in Mice and Sows of Enterotoxigenic Escherichia Coli Outer-Membrane Vesicles Incorporated into Zein-Based Nanoparticles
  35. Modulation of the fate of zein nanoparticles by their coating with a Gantrez® AN-thiamine polymer conjugate
  36. Evaluation of Skin Permeation and Retention of Topical Dapsone in Murine Cutaneous Leishmaniasis Lesions
  37. Dissolving Microneedles for Intradermal Vaccination against Shigellosis
  38. Casein nanoparticles in combination with 2-hydroxypropyl-β-cyclodextrin improves the oral bioavailability of quercetin
  39. Nanoparticles from Gantrez® AN-poly(ethylene glycol) conjugates as carriers for oral delivery of docetaxel
  40. In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization
  41. Mannosylated Nanoparticles for Oral Immunotherapy in a Murine Model of Peanut Allergy
  42. In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)
  43. The effect of thiamine-coating nanoparticles on their biodistribution and fate following oral administration
  44. Understanding the basis of transcutaneous vaccine delivery
  45. Towards a subunit vaccine from a Shigella flexneri ΔtolR mutant
  46. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions
  47. Increased Oral Bioavailability of Resveratrol by Its Encapsulation in Casein Nanoparticles
  48. Cyclodextrin-grafted poly(anhydride) nanoparticles for oral glibenclamide administration. In vivo evaluation using C. elegans
  49. Pegylated poly(anhydride) nanoparticles for oral delivery of docetaxel
  50. Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice
  51. Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy
  52. Human serum albumin nanoparticles for ocular delivery of bevacizumab
  53. Coencapsulation of cyclodextrins into poly(anhydride) nanoparticles to improve the oral administration of glibenclamide. A screening on C. elegans
  54. Evaluation of the treatment with resveratrol-loaded nanoparticles in intestinal injury model caused by ischemia and reperfusion
  55. Poly(anhydride) nanoparticles containing cashew nut proteins can induce a strong Th1 and Treg immune response after oral administration
  56. Soybean protein-based microparticles for oral delivery of probiotics with improved stability during storage and gut resistance
  57. Maternal Vaccination. Immunization of Sows during Pregnancy against ETEC Infections
  58. Special Issue: Pharmaceutics and Drug Delivery in Spain
  59. A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles
  60. Optimization and evaluation of zein nanoparticles to improve the oral delivery of glibenclamide. In vivo study using C. elegans
  61. Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis
  62. Corrigendum to ‘Evaluation of the cytotoxicity, genotoxicity and mucus permeation capacity of several surface modified poly(anhydride) nanoparticles designed for oral drug delivery’ [International Journal of Pharmaceutics 517 (2017) 67-79]
  63. Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.
  64. Genotoxic evaluation of poly(anhydride) nanoparticles in the gastrointestinal tract of mice
  65. Supramolecular structure of glibenclamide and β-cyclodextrins complexes
  66. Adjuvants for allergy immunotherapeutics
  67. Effective protection of mice against Shigella flexneri with a new self-adjuvant multicomponent vaccine
  68. Toxicity and biodistribution of orally administered casein nanoparticles
  69. Zein nanoparticles as vehicles for oral delivery purposes
  70. In vitro evaluation of the genotoxicity of poly(anhydride) nanoparticles designed for oral drug delivery
  71. Nanoaggregation of inclusion complexes of glibenclamide with cyclodextrins
  72. Topical immunization using a nanoemulsion containing bacterial membrane antigens
  73. Improved effect of amikacin-loaded Poly (D, L-lactide-co-glycolide) (PLGA) nanoparticles against Planktonic and biofilm cells of Pseudomonas aeruginosa
  74. Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer’s disease
  75. Evaluation of the cytotoxicity, genotoxicity and mucus permeation capacity of several surface modified poly(anhydride) nanoparticles designed for oral drug delivery
  76. Zein nanoparticles for oral delivery of quercetin: Pharmacokinetic studies and preventive anti-inflammatory effects in a mouse model of endotoxemia
  77. New pharmaceutical approaches for the treatment of food allergies
  78. Amikacin loaded PLGA nanoparticles against Pseudomonas aeruginosa
  79. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells
  80. Synthesis of Electroneutralized Amphiphilic Copolymers with Peptide Dendrons for Intramuscular Gene Delivery
  81. Oral delivery of camptothecin using cyclodextrin/poly(anhydride) nanoparticles
  82. Zein nanoparticles for oral folic acid delivery
  83. Study of Thermal Degradation of PLGA, PLGA Nanospheres and PLGA/Maghemite Superparamagnetic Nanospheres
  84. Interactions of poly (anhydride) nanoparticles with macrophages in light of their vaccine adjuvant properties
  85. In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration
  86. Assessment of β-lapachone loaded in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis in L. major infected BALB/c mice
  87. Toxicity evaluation of nanocarriers for the oral delivery of macromolecular drugs
  88. Mimicking microbial strategies for the design of mucus-permeating nanoparticles for oral immunization
  89. Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles
  90. Abstract 4067: Pluronic micelle-encapsulated Disulfiram targets cancer stem-like cells and reverses pan-resistance in acquired resistant breast cancer cell lines
  91. Zein-Based Nanoparticles Improve the Oral Bioavailability of Resveratrol and Its Anti-inflammatory Effects in a Mouse Model of Endotoxic Shock
  92. Casein nanoparticles as carriers for the oral delivery of folic acid
  93. Co-Encapsulated CpG Oligodeoxynucleotides and Ovalbumin in PLGA Microparticles; An in vitro and in vivo Study
  94. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation
  95. Nanoparticles as Adjuvants for Vaccination
  96. Development of a Bacterial Nanoparticle Vaccine
  97. Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo
  98. Nanoparticle based-immunotherapy against allergy
  99. Pharmacokinetics and antitumor efficacy of paclitaxel–cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration
  100. Immunogenicity of Peanut Proteins Containing Poly(Anhydride) Nanoparticles
  101. Influence of Cyclodextrin Derivatives on In Vitro Release of Cyclosporine A from Poly(anhydride) Nanoparticles
  102. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis
  103. Vaccine Delivery Systems for Veterinary Immunization
  104. Thermosensitive hydrogels of poly(methyl vinyl ether-co-maleic anhydride) – Pluronic® F127 copolymers for controlled protein release
  105. Superparamagnetic maghemite loaded poly (?- caprolactone) nanocapsules : characterization and synthesis optimization
  106. PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania
  107. Antigen Delivery Systems as Oral Adjuvants
  108. Cytotoxicity and Cell Interaction Studies of Bioadhesive Poly(anhydride) Nanoparticles for Oral Antigen/Drug Delivery
  109. Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice
  110. Optimization of maghemite-loaded PLGA nanospheres for biomedical applications
  111. Towards a non-living vaccine against Shigella flexneri: From the inactivation procedure to protection studies
  112. Nanoparticules mucopénétrantes : véhicules pour l’administration orale du paclitaxel
  113. Radiomarcaje y estudios de biodistribución de nanopartículas poliméricas como adyuvantes para la vacunación oftálmica frente a la brucelosis
  114. Poly(ethylene oxide)-block-poly(n-butyl acrylate)-block-poly(acrylic acid) triblock terpolymers with highly asymmetric hydrophilic blocks: synthesis and aqueous solution properties
  115. Recent progress towards development of aShigellavaccine
  116. Development of poly(anhydride) nanoparticles loaded with peanut proteins: The influence of preparation method on the immunogenic properties
  117. Stabilized micelles as delivery vehicles for paclitaxel
  118. Conjunctival vaccination against Brucella ovis in mice with mannosylated nanoparticles
  119. Innovative Lead Compounds and Formulation Strategies As Newer Kinetoplastid Therapies
  120. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: Permeability and pharmacokinetic study
  121. Low efficacy of NcGRA7, NcSAG4, NcBSR4 and NcSRS9 formulated in poly-ɛ-caprolactone against Neospora caninum infection in mice
  122. Toxicity Studies of Poly(Anhydride) Nanoparticles as Carriers for Oral Drug Delivery
  123. Nuevas formas farmacéuticas para el tratamiento de enfermedades alérgicas
  124. Chapter 2.3. Nanostructures for Oral Vaccine Delivery
  125. Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease
  126. Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy
  127. Molecular buckets: cyclodextrins for oral cancer therapy
  128. Gantrez AN Nanoparticles for Ocular Delivery of Memantine: In vitro Release Evaluation in Albino Rabbits
  129. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice
  130. Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators
  131. Nanomedicine: Novel approaches in human and veterinary therapeutics
  132. Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone
  133. Bioadhesive properties of poly(anhydride) nanoparticles coated with different molecular weights chitosan
  134. Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery
  135. Nanoparticles for the Oral Administration of Cancer Therapies
  136. Molecular Imaging Techniques to Study the Biodistribution of Orally Administered 99mTc-Labelled Naive and Ligand-Tagged Nanoparticles
  137. Poly(Anhydride) Nanoparticles Act as Active Th1 Adjuvants through Toll-Like Receptor Exploitation
  138. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles
  139. Toxicity studies of poly(anhydride) nanoparticles
  140. Influence of dextran on the bioadhesive properties of poly(anhydride) nanoparticles
  141. Evaluation of particulate acellular vaccines against Brucella ovis infection in rams
  142. Influence of the chitosan nature on the transfection efficacy of DNA-loaded nanoparticles after hydrodynamic administration in mice
  143. Different approaches for determination of the attachment degree of polyethylene glycols to poly(anhydride) nanoparticles
  144. Poly anhydride nanoparticles as adjuvants for mucosal vaccination
  145. Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel
  146. New adjuvants: from empiricism to science
  147. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne
  148. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination
  149. Design and influence of γ-irradiation on the biopharmaceutical properties of nanoparticles containing an antigenic complex from Brucella ovis
  150. Bioadhesive properties and biodistribution of cyclodextrin–poly(anhydride) nanoparticles
  151. Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl β-1,6 glucosamine specific antibody production using biofilm-embedded bacteria
  152. Co-Delivery of Ovalbumin and CpG Motifs into Microparticles Protected Sensitized Mice from Anaphylaxis
  153. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis
  154. Stability of Poly(ε-caprolactone) Microparticles Containing Brucella ovis Antigens as a Vaccine Delivery System Against Brucellosis
  155. New methodologies to characterize the effectiveness of the gene transfer mediated by DNA-chitosan nanoparticles
  156. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology
  157. Evaluation of Bioadhesive Capacity and Immunoadjuvant Properties of Vitamin B12-Gantrez Nanoparticles
  158. Mannose-targeted systems for the delivery of therapeutics
  159. Nanomedicina: nanopartículas con aplicaciones médicas
  160. Development of bioadhesive amino-pegylated poly(anhydride) nanoparticles designed for oral DNA delivery
  161. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles
  162. Albumin Nanoparticles
  163. Plant Protein-based Nanoparticles
  164. An HPLC with evaporative light scattering detection method for the quantification of PEGs and Gantrez in PEGylated nanoparticles
  165. Lyophilization of adenoviral vectors for gene therapy
  166. Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens
  167. Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice
  168. Evaluation of bioadhesive potential and intestinal transport of pegylated poly(anhydride) nanoparticles
  169. Nanoparticles as Adjuvant-Vectors for Vaccination
  170. Intradermal immunization with ovalbumin-loaded poly-?-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice
  171. Gamma Interferon Loaded onto Albumin Nanoparticles: In Vitro and In Vivo Activities against Brucella abortus
  172. Encapsulation of antigenic extracts of Salmonella enterica serovar
  173. Chemical and Biological Factors in the Control of Brucella and Brucellosis
  174. Bioadhesive Mannosylated Nanoparticles for Oral Drug Delivery
  175. Development of a Novel Vaccine Delivery System Based on Gantrez Nanoparticles
  176. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice
  177. Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams
  178. Optimization of the entrapment of bacterial cell envelope extracts into microparticles for vaccine delivery
  179. Simultaneous quantification of different cyclodextrins and Gantrez by HPLC with evaporative light scattering detection
  180. Salmonella-like bioadhesive nanoparticles
  181. Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice
  182. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties
  183. Bioadhesive properties of pegylated nanoparticles
  184. Albumin Nanoparticles for the Intravitreal Delivery of Anticytomegaloviral Drugs
  185. Potential of Albumin Nanoparticles as Carriers for Interferon Gamma
  186. Protective ability of subcellular extracts from Salmonella Enteritidis and from a rough isogenic mutant against salmonellosis in mice
  187. Bioadhesive Properties of Gantrez Nanoparticles
  188. Potential of Albumin Nanoparticles as Carriers for Interferon Gamma
  189. Humoral immune response in hens naturally infected withSalmonellaEnteritidis against outer membrane proteins and other surface structural antigens
  190. Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes
  191. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines
  192. New Therapeutic Approaches for the Treatment of Brucella Infections: Gentamicin Entrapment into Drug Delivery Systems
  193. Influence of the co-encapsulation of different excipients on the properties of polyester microparticle-based vaccine against brucellosis
  194. In vivo sustained release of adenoviral vectors from poly(d,l-lactic-co-glycolic) acid microparticles prepared by TROMS
  195. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide
  196. Fluconazole encapsulation in PLGA microspheres by spray-drying
  197. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice
  198. Bovine Serum Albumin Modified the Intracellular Distribution and Improved the Antiviral Activity of an Oligonucleotide
  199. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties
  200. Corrigendum to: “Gantrez® AN as a new polymer for the preparation of ligand–nanoparticle conjugates”
  201. Loading of plasmid DNA into PLGA microparticles using TROMS (Total Recirculation One-Machine System): evaluation of its integrity and controlled release properties
  202. Modulation of the cellular immune response after oral or subcutaneous immunization with microparticles containing Brucella ovis antigens
  203. Gantrez® AN as a new polymer for the preparation of ligand–nanoparticle conjugates
  204. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide
  205. Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis
  206. Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles
  207. RP–LC determination of 5-fluorouridine in nanoparticulate formulations
  208. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats
  209. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres
  210. Polyester Microparticles as a Vaccine Delivery System for Brucellosis: Influence of the Polymer on Release, Phagocytosis and Toxicity
  211. Efficacy of Ganciclovir-loaded Nanoparticles in Human Cytomegalovirus (HCMV)-infected Cells
  212. Adaptive Immune Responses of Legumin Nanoparticles
  213. In Vitro Antileishmanial Activity of Amphotericin B Loaded in Poly(ε-Caprolactone) Nanospheres
  214. A Brucella ovis antigenic complex bearing poly-ε-caprolactone microparticles confer protection against experimental brucellosis in mice
  215. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties
  216. Rapid determination of intramacrophagic amphotericin B by direct injection HPLC
  217. Bioadhesive potential of gliadin nanoparticulate systems
  218. In Vitro Reversion of Amphotericin B Resistance in Leishmania donovani by Poloxamer 188
  219. RESEARCH NOTE - Evaluation and Characterisation of Gliadin Nanoparticles and Isolates by Reversed-Phase HPLC
  220. Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections
  221. Determination of oligonucleotide ISIS 2922 in nanoparticulate delivery systems by capillary zone electrophoresis
  222. Development of a sensitive method for the determination of ganciclovir by reversed-phase high-performance liquid chromatography
  223. Biopolymer and polymer nanoparticles and their biomedical applications
  224. Distribution of Albumin Nanoparticles in Animals Induced with the Experimental Allergic Encephalomyelitis
  225. Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus
  226. Electrophoretic separation and characterisation of gliadin fractions from isolates and nanoparticulate drug delivery systems
  227. Gliadin nanoparticles: formation, all‐ trans‐retinoic acid entrapment and release, size optimization
  228. Gliadin nanoparticles: formation, all-trans-retinoic acid entrapment and release, size optimization
  229. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract
  230. Interaction of amphotericin B with polymeric colloids
  231. Interaction of amphotericin B with polymeric colloids: 2. Effect of poloxamer on the adsorption of amphotericin B onto poly(ϵ-caprolactone) nanospheres
  232. Development of Drug-delivery Systems from Vegetal Proteins: All-trans-retinoic Acid-loaded Gliadin Nanoparticles
  233. Poly(ε-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity
  234. Preparation of lectin-vicilin nanoparticle conjugates using the carbodiimide coupling technique
  235. Gliadin nanoparticles for the controlled release of all-trans-retinoic acid
  236. Development of Drug Delivery Systems from Vegetal Proteins: Legumin Nanoparticles
  237. Optimization and in vitro stability of legumin nanoparticles obtained by a coacervation method
  238. Mucin Interactions with Functionalized Polystyrene Latexes
  239. In vitro study of lectin-latex conjugates for specific bioadhesion
  240. Preparation and characterization of lectin-latex conjugates for specific bioadhesion
  241. Stability of some phenolic antioxidants in fatty preparations
  242. Determination of particle concentration in latexes by turbidimetry
  243. HPLC determination of antioxidant synergists and ascorbic acid in some fatty pharmaceuticals, cosmetics and food
  244. NANOPARTICLES FOR ORAL VACCINATION
  245. Study of the interactions between nanoparticles and intestinal mucosa